Thymosin alpha-1 is not FDA approved — and that sentence, alone, misleads. The same 28-amino-acid peptide is marketed as the drug thymalfasin (Zadaxin) across dozens of countries, holds an EU orphan designation, and has decades of clinical-trial history. What it lacks is a completed US approval — and, lately, a settled compounding status.
As of 2026, thymosin alpha-1 has no FDA approval for any indication. It is approved abroad as thymalfasin, carries an EMA orphan designation for hepatocellular carcinoma, and its US availability runs through the compounding system — which is exactly where FDA's Pharmacy Compounding Advisory Committee activity in 2026 puts it under live review.
The US answer: not approved, and never has been
No thymosin alpha-1 product has completed FDA approval — a status unchanged across three decades of clinical work. Its US clinical history is real — hepatitis programs ran multicenter trials, and sepsis and COVID-19 cohorts added ICU data — but a completed US marketing application never followed. In FDA terms it is an unapproved drug substance, full stop.
That leaves two lawful US lanes: research use, and pharmacy compounding under section 503A — the lane where the current action is.
The compounding fight: 503A and the 2026 advisory calendar
Compounding pharmacies may only use bulk substances that are the subject of an applicable monograph, components of approved drugs, or entries on FDA's 503A bulk-substances list. Thymosin alpha-1's place on that map is being contested in real time: FDA's Pharmacy Compounding Advisory Committee docketed peptide bulk substances across its 2026 meetings, with an April notice establishing the docket and a July session on the calendar.
The practical stakes: a negative committee outcome narrows the clinic-compounding lane that has carried most US thymosin alpha-1 use, while research-use supply is unaffected by the compounding question. Watching the docket is watching the future of US access.
Everywhere else: thymalfasin's approvals
Outside the US the molecule is a marketed pharmaceutical — thymalfasin, brand name Zadaxin — with approvals across 30+ countries, concentrated in hepatitis B and C and as an immune adjuvant. Europe adds a formal orphan designation: EU/3/02/110, granted in 2002 for hepatocellular carcinoma, a designation that shapes development incentives rather than granting marketing approval itself.
The evidence that keeps it in play
Three strands explain why regulators keep engaging with a decades-old peptide. Hepatitis: multicenter randomized programs in chronic B and C, including combination-therapy trials in prior non-responders. Critical illness: the ETASS multicenter randomized trial in severe sepsis reported a mortality signal worth follow-up, and COVID-era cohort data in critically ill patients kept the immune-restoration hypothesis current. And the mechanism literature — reviewed at length in 2020 and revisited in 2024 as a case study in phenotypic drug discovery — keeps supplying biological rationale for indications the trials haven't settled.
Research peptides
Research-use-only peptides with batch-matched certificates of analysis — the documentation lane the compounding debate never touches.
How to read "not FDA approved" on a research vial
For a US buyer of research material, the status line means exactly this: the compound is an unapproved drug substance whose clinical literature is unusually deep for the research-peptide market; its foreign approvals do not transfer; and the compounding controversy governs clinics, not laboratories. A research vial's paperwork stands on its own COA — the regulatory map above is context, never a claim.
Research peptides
Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.
What to know now
- No FDA approval — thymosin alpha-1 has never completed a US marketing application, for any indication.
- Abroad it is the approved drug thymalfasin (Zadaxin), marketed in dozens of countries, plus an EMA orphan designation (EU/3/02/110, hepatocellular carcinoma).
- US access runs through 503A compounding — and FDA's Pharmacy Compounding Advisory Committee put peptide bulk substances on its 2026 docket.
- The trial base is real: multicenter hepatitis programs, the ETASS sepsis RCT, COVID-19 ICU cohorts.
- Foreign approvals do not transfer; a research vial's evidentiary document is its COA, not the regulatory map.
What we're watching
The Pharmacy Compounding Advisory Committee's 2026 outcomes on peptide bulk substances — the single decision most likely to redraw US thymosin alpha-1 access, in either direction.
Frequently asked questions
Is thymosin alpha-1 FDA approved in 2026?
No. Thymosin alpha-1 has no FDA approval for any indication as of 2026. It is approved in dozens of other countries as thymalfasin (Zadaxin), and in the US it circulates through research supply and — contentiously — pharmacy compounding.
Why was thymosin alpha-1 in the news with FDA?
Because of compounding, not approval: FDA's Pharmacy Compounding Advisory Committee docketed peptide bulk substances during its 2026 meeting cycle, a process that decides whether compounding pharmacies may keep preparing it under section 503A.
What is thymalfasin?
Thymalfasin is the pharmaceutical name for synthetic thymosin alpha-1 — the same 28-amino-acid peptide — marketed abroad as Zadaxin, with approvals concentrated in chronic hepatitis B and C and immune-adjuvant use.
Does the EU orphan designation mean it is approved in Europe?
No. Orphan designation EU/3/02/110 (2002, hepatocellular carcinoma) grants development incentives; it is not a marketing authorization.
References
- European Medicines Agency. Orphan designation EU/3/02/110 — thymalfasin for the treatment of hepatocellular carcinoma, designated 30 July 2002. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu302110
- Ciancio, A., Andreone, P., Kaiser, S., et al. (2012). Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: An adjuvant role? Journal of Viral Hepatitis, 19(Suppl. 1), 52–59. https://doi.org/10.1111/j.1365-2893.2011.01524.x
- Iino, S., Toyota, J., Kumada, H., et al. (2005). The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B: Results from a randomized clinical trial. Journal of Viral Hepatitis, 12(3), 300–306. https://doi.org/10.1111/j.1365-2893.2005.00633.x
- Wu, J., Zhou, L., Liu, J., et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): A multicenter, single-blind, randomized and controlled trial. Critical Care, 17(1), R8. https://doi.org/10.1186/cc11932
- Wu, M., Ji, J. J., Zhong, L., et al. (2020). Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study. International Immunopharmacology, 88, 106873. https://doi.org/10.1016/j.intimp.2020.106873
- Dominari, A., Hathaway III, D., Pandav, K., et al. (2020). Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology, 9(5), 67–78. https://doi.org/10.5501/wjv.v9.i5.67
- Garaci, E., Paci, M., Matteucci, C., et al. (2024). Phenotypic drug discovery: A case for thymosin alpha-1. Frontiers in Medicine, 11, 1388959. https://doi.org/10.3389/fmed.2024.1388959
- Food and Drug Administration. (2026, April 16). Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. Federal Register, document 2026-07361. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- U.S. Food and Drug Administration. (2026). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- U.S. Food and Drug Administration. (2024). Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
- U.S. Food and Drug Administration. (2024). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding